New FDA Approval for Tremfya in Crohn's Disease
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease (CD).
Tremfya is now the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options for CD.
This is Tremfya's fourth FDA-approved indication, following plaque psoriasis, psoriatic arthritis, and ulcerative colitis.
Key Clinical Data
Approval was based on multiple Phase 3 trials involving over 1,300 CD patients.
In the GRAVITI study, subcutaneous Tremfya showed significantly better clinical remission and endoscopic response than placebo.
The GALAXI trials demonstrated Tremfya's superiority over Stelara (ustekinumab) on all pooled endoscopic endpoints.
Positioning as Stelara Successor
This approval advances J&J's efforts to position Tremfya as a successor to Stelara, which faces biosimilar competition.
Stelara was J&J's top-selling drug in 2023 with $10.9 billion in sales.
Tremfya is expected to help offset revenue loss as Stelara biosimilars enter the market in 2025.
Implications
Expands treatment options for Crohn's disease patients.
Strengthens J&J's immunology portfolio as Stelara sales decline.
Positions Tremfya to compete with other IL-23 inhibitors like AbbVie's Skyrizi in the inflammatory bowel disease market.